Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
BUSINESS
Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
In its consolidated settlement of accounts for June–November 2011 announced on December 26, Nippon Kayaku’s pharmaceutical business posted sales of ¥24,764 million (-0.4% over the corresponding period of the previous year) and segment profits of ¥4,976 million (-4.4%). Sales increased…
To read the full story
BUSINESS
- Real-World Data Confirms Efficacy of Cefiderocol in Drug-Resistant Bacteria
October 18, 2024
- Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
- Doshisha Offshoot Eyes Nationwide Delivery of Cryopreserved Cell Product for Bullous Keratopathy
October 17, 2024
- Eisai Alzheimer’s Drug Hits Another Snag, This Time in Australia
October 17, 2024
- Shinya Nagase Named New Skipper of BD Japan
October 17, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…